Lockhart, A., Liu, Y., Dehdashti, F., Laforest, R., Picus, J., Frye, J., . . . Siegel, B. A. (2016). Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors. Molecular Imaging & Biology, 18(3), 446-454.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Lockhart, A., et al. "Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors."
Molecular Imaging & Biology 18, no. 3 (2016): 446-454.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Lockhart, A., et al. "Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors."
Molecular Imaging & Biology, vol. 18, no. 3, 2016, pp. 446-454.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.